Fundraising Fox
Summit Therapeutics
NASDAQ: SMMTMiami, US · Founded 2020 · Delaware corporation · 394 employees on LinkedIn · 1 known investors
Find your way into Summit Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
735 people can intro you to Manmeet
Ask Paul LaViolette to introduce you to Manmeet Soni
You →Paul · together at Pulse Biosciences, Inc. →Manmeet
251 people can intro you to David
Ask Jamie Chen to introduce you to David Roblin
You →Jamie · together at Centauri Therapeutics →David
Sign up to find every way you can get introduced to Summit Therapeutics
- Your email: who you already know at Summit Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Summit Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Summit Therapeutics is a biopharmaceutical oncology company developing and commercializing cancer therapies, with a lead candidate, ivonescimab (SMT112/AK112), a bispecific antibody targeting PD-1 and VEGF currently in Phase 3 trials for non-small cell lung cancer. It licenses ivonescimab from Akeso for territories including the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
Founders & leadership
MS
Manmeet SoniChief Operating Officer and Board MemberManmeet Soni is Chief Operating and Financial Officer at Summit Therapeutics, where he oversees finance, clinical operations, manufacturing, and commercial functions. He has held CFO and COO roles at multiple biopharmaceutical companies including Reata Pharmaceuticals (where he helped orchestrate its $7.5 billion acquisition by Biogen), Alnylam Pharmaceuticals, ARIAD Pharmaceuticals, and Pharmacyclics, and previously worked in venture capital and assurance services at PwC.
MZ
Mahkam ZanganehExecutive
DR
David RoblinCOO, CMO & President of R&D2013–2020David Roblin is an oncologist and pharmaceutical executive with experience spanning academia, biotech, and pharma. He previously served as COO and Chair of Scientific Translation at the Francis Crick Institute and as Head of European R&D at Pfizer, and holds board positions at multiple life sciences companies.
RW
Robert W. DugganCo-Chief Executive Officer and Chairman of the Board of Directors
DW
David WurzerNamed on SEC filing
LZ
Leopoldo ZambelettiNamed on SEC filing
VA
Valerie AndrewsNamed on SEC filing
FA
Frank ArmstrongNamed on SEC filing
GE
Glyn EdwardsNamed on SEC filing
Board
JM
Jim MellonBoard director
JH
Investors · 1
Triatomic CapitalreportedPalo Alto · $100K – $1M
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$1.1B disclosed across 7 of 8 rounds · 2014–2026
▶$235MraisedSep 2024 · 17 investors · BiotechnologyRule 506(b)
▶$235MraisedSep 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Manmeet SoniExecutive Officer, Director
- Robert DugganExecutive Officer, Director
- Jeff HuberDirector
- Mahkam ZanganehExecutive Officer, Director
- Mostafa RonaghiDirector
- Alessandra CesanoDirector
- Kenneth ClarkDirector
- Yu XiaDirector
- Robert BoothDirector
- Offering amount
- $235M
- Amount sold
- $235M
- Proceeds to insiders
- $75.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$200MraisedJun 2024 · 2 investors · BiotechnologyRule 506(b)
▶$200MraisedJun 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yu XiaDirector
- Ujwala MahatmeDirector
- Manmeet SoniExecutive Officer, Director
- Mostafa RonaghiDirector
- Robert DugganExecutive Officer, Director
- Mahkam ZanganehExecutive Officer, Director
- Kenneth ClarkDirector
- Alessandra CesanoDirector
- Robert BoothDirector
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$50MraisedNov 2020 · 3 investors · BiotechnologyRule 506(b)
▶$50MraisedNov 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert DugganExecutive Officer
- Mahkam ZanganehDirector
- Rainer ErdtmannDirector
- Manmeet SoniDirector
- Ujwala MahatmeDirector
- Michael Paul DonaldsonExecutive Officer
- Houbiers JosExecutive Officer
- David Johnathan PowellExecutive Officer
- Camilla GrahamExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$47.4MraisedJan 2020 · 1 investors · BiotechnologyRule 506(b)
▶$47.4MraisedJan 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David RoblinExecutive Officer
- Robert W. DugganDirector
- Elaine StrackerDirector
- Glyn EdwardsExecutive Officer, Director
- Manmeet SoniDirector
- Daniel ElgerExecutive Officer
- Ventzislav StefanovDirector
- Offering amount
- $47.4M
- Amount sold
- $47.4M
- First sale
- Dec 2019
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
▶$25MraisedJan 2019 · 1 investors · BiotechnologyRule 506(b)
▶$25MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David WurzerDirector
- Leopoldo ZambelettiDirector
- David RoblinExecutive Officer
- Valerie AndrewsDirector
- Frank ArmstrongDirector
- Glyn EdwardsExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Jan 2019
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
▶$11.6MraisedMar 2014 · 13 investors · BiotechnologyRule 506(b)
▶$11.6MraisedMar 2014 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen DaviesDirector
- Jim MellonDirector
- Raymond SpencerExecutive Officer
- Frank ArmstrongDirector
- Glyn EdwardsExecutive Officer, Director
- Barry PriceDirector
- Offering amount
- $11.6M
- Amount sold
- $11.6M
- Sales commissions
- $698.6K
- Placement agents
- JMP Securities LLC
- First sale
- Mar 2014
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Summit Therapeutics went on to found or lead other companies.
Related companies · 2
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Summit Therapeutics.
In the news
Frequently asked questions
- What does Summit Therapeutics do?
- Summit Therapeutics is a biopharmaceutical oncology company developing and commercializing cancer therapies, with a lead candidate, ivonescimab (SMT112/AK112), a bispecific antibody targeting PD-1 and VEGF currently in Phase 3 trials for non-small cell lung cancer. It licenses ivonescimab from Akeso for territories including the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
- Who are Summit Therapeutics's investors?
- Summit Therapeutics's investors include Triatomic Capital.
- How much funding has Summit Therapeutics raised?
- Summit Therapeutics has disclosed $1.1B raised across 7 of its 8 known rounds.
- Where is Summit Therapeutics headquartered?
- Summit Therapeutics is headquartered in Miami, US.